• Praxis Precision Medicines and Remagine Labs recently entered a research collaboration and license agreement to develop an iontophoretic transdermal patch delivering ulixacaltamide for essential tremor, alongside Praxis's existing oral program, with Praxis also taking an equity stake in Remagine Labs.
• This move signals Praxis's effort to broaden ulixacaltamide's treatment reach and potentially strengthen the long-term value of its essential tremor franchise through alternative delivery technology.
• We’ll now examine how the new ulixacaltamide transdermal patch collaboration could reshape Praxis Precision Medicines’ existing investment narrative and future outlook.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis, you have to believe its late stage CNS pipeline can turn today’s losses into future cash flows, with ulixacaltamide and the epilepsy portfolio at the center. The new Remagine Labs transdermal patch collaboration broadens the ulixacaltamide story, but it does not change that the most important near term regulatory catalyst is the relutrigine NDA review extension, while the biggest risk remains execution and setbacks across a small group of key programs.

The recent FDA decision to extend the relutrigine NDA review to December 27, 2026 is the most relevant backdrop for this new ulixacaltamide update. While the patch collaboration adds another potential asset to Praxis’s essential tremor franchise, the timing and outcome of the relutrigine decision still loom large as a nearer regulatory milestone, especially for a company that continues to post sizable net losses as it funds multiple late stage CNS programs.

Yet against this expanding pipeline story, investors should also be aware of the risk that setbacks in any of Praxis’s few late stage CNS assets could…

Praxis Precision Medicines’ narrative projects $1.4 billion revenue and $434.2 million earnings by 2029. This implies an earnings increase of about $760.7 million from -$326.5 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $617.67 fair value, a 91% upside to its current price.

Exploring Other Perspectives

Before this patch news, the most pessimistic analysts were assuming revenue of about US$76.6 million and earnings near US$12.3 million by 2028, so if you worry about heavy cash burn and trial risk while others focus on ulixacaltamide’s upside, you are seeing how far opinions can diverge.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.